Abstract
Flovatriptan is a selective agonist of the receptors 5-HT1B/1D. It is effective in acute treatment of migraine attacks and its accompanying symptoms, such as nausea, photophobia and phonophobia.
Flovatriptan?s pharmacokinestetic characteristics are similar to those of other triptans with the difference that Flovatriptan surpasses by its long biological half-life elimination (around 26 hours) and therefore there is a very low presence of migraine attack recurrences. Flovatriptan is well tolerated in the usual dose (2,5 mg) and the presence of adverse effects is similar to those during placebo administration.
Flovatriptan is an effective miniprophylactic agent in pharmaco-resistant menstrual migraines (application: 2,5 mg, up to 5 mg daily for 2 days before menstrual bleeding and then four days following menstrual bleeding).